AKT1 and acute lymphoblastic leukemia: In contrast to their effects on Jurkat cells, used as a positive control, the dual inhibitors NVP-BGT226 and NVP-BEZ235, failed to dephosphorylate AKT in ALL-LTCs, similar to the selective PI3K and mTORC1 inhibition.